Osimertinib-chemotherapy extends PFS for EGFR-, TP53-mutant NSCLC

COPENHAGEN, Denmark — Adding chemotherapy to first-line osimertinib significantly improved survival for patients with EGFR-mutated advanced non-small cell lung cancer who also have TP53 mutations.
Findings from the randomized phase 3 TOP study, presented at European Lung Cancer Congress, showed adults treated with combination therapy had a 56% improvement in PFS compared with those who received osimertinib (Tagrisso, AstraZeneca) monotherapy.
OS trends significantly favored the combination arm, too, though the regimen did substantially increase toxicities.
“These findings provide key evidence to







